Miners J O, Lillywhite K J
Department of Clinical Pharmacology, Flinders Medical Centre, Bedford Park, Adelaide, Australia.
Biochem Pharmacol. 1991 Mar 1;41(5):838-41. doi: 10.1016/0006-2952(91)90090-r.
The data suggest that the 4MU-UDPGT activity of human liver microsomes probably contributes to the glucuronidation of a limited number of clinically used drugs. However, confirmation of this ultimately requires studies to be performed with purified isozymes, cDNAs expressed in cell culture, or specific inhibitory antibodies.
数据表明，人肝微粒体的4MU-UDPGT活性可能有助于少数临床使用药物的葡萄糖醛酸化。然而，最终证实这一点需要使用纯化的同工酶、在细胞培养中表达的cDNA或特异性抑制抗体进行研究。
